Acusphere
date acquired 9/30/02
date sold open market
ROI: 8x |
|
Aquacap
102,564 common
8,010 Series A Preferred
Warrant to purchase 30,000 common
date acquired 9/30/02
date sold
ROI: 10x
|
|
Chromos Molecular
240,000 shares
ROI: 2x |
|
Cogent Neurosciences Inc.
date acquired 9/30/02
Filed chapter 7 liquidation same day
1,161,922 ELN-1 Preferred
8,010 series A Preferred
Warrant to acquire 46,729 common
ROI: total loss |
|
Cytokine Pharmasciences
date acquired 9/30/02
67,789 Common Shares
250 shares Series A preferred
Warrants to acquire
30,000 common shares
date sold
ROI: 22.4x |
|
Elite Pharmaceuticals
date acquired 9/30/02
799,291 common shares
Open market sales 03/05-04/05
ROI: 5.5x |
|
FeRx
date acquired 9/30/02
675,675 shares series D Preferred
1,001,252 shares Series E Preferred
company filed chapter 7 liquidation
ROI: total loss of investment |
|
Ingredient Innovation International
sold back to the company
ROI: loss of 50% of invested capital |
|
Medisys PLC
date acquired 9/30/02
5,172,874 ordinary shares
dates sold 4-5/03
ROI: 5x |
|
Neurome
date acquired 9/30/02
428,571 series B shares
616,154 Series BB shares
Warrants to acquire 50,000
common shares
sold back to the company
ROI: 22x |
|
Vernalis
date acquired 9/30/02
2,943,396 ordinary shares
open market sales 11/02
ROI: 6x |
|
|
|
|
John Moore shares the lessons he is learning as a value investor in emerging growth companies.
|
Wilmington Scientific
Investing in promising emerging growth companies in healthcare, energy and consumer products. |
Edson Moore
Healthcare Ventures
403 Marsh Lane
Wilmington, DE 19804
|
|
